The ENZAp trial, a randomized controlled phase 2 trial evaluating [177Lu]Lu-PSMA-617 in addition to enzalutamide in men with high-risk metastatic castration-resistant prostate cancer, was conducted at 15 sites in Australia. The gene discussed is FOLH1; the disease is Familial prostate cancer.